Clinical trials: RA - Rheumatoid Arthritis
Arthritis, Rheumatoid
A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis
To evaluate the efficacy, safety and tolerability of CP-195543 and celecoxib dual therapy in subjects with rheumatoid arthritis
- Trial name
- NCT00424294
- Testing
- CP-195,543, celecoxib, Methotrexate
- Where
- 39 sites in United States
- Volunteers
- 70 people
- Sponsor
- Pfizer
Rheumatoid Arthritis &Amp; Other Inflammatory Polyarthropathies, Peripheral Spondyloarthritis
Automated Arthritis Detection Using Artificial Intelligence on Smartphone Photographs
The investigators are testing the ability of convolutional neural networks (CNNs), that is artificial intelligence, on smartphone photographs in detecting inflammatory arthritis.
- Conditions
- Rheumatoid Arthritis &Amp; Other Inflammatory Polyarthropathies, Peripheral Spondyloarthritis, Inflammatory Arthritis
- Trial name
- AISynovitis (NCT06715488)
- Testing
- AI assisted smartphone diagnosis
- Where
- 2 sites in India
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Med2Measure
Active Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Trial name
- NCT07409103
- Testing
- ELV001 25 mg, ELV001 75 mg, ELV001 125 mg
- Where
- 34 sites in United States, Serbia and 1 more
- Volunteers
- 180 people
- Sponsor
- Elevara Medicines Limited
Arthritis, Rheumatoid
A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis
This study is designed to look at the safety, tolerability and effectiveness of 28 days of dosing of GW856553 in rheumatoid arthritis patients.
- Trial name
- NCT00393146
- Testing
- GW856553
- Where
- 15 sites in Romania, Russia and 1 more
- Volunteers
- 57 people
- Sponsor
- GlaxoSmithKline
Arthritis, Rheumatoid
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
The primary objective of the study is to compare, in patients treated with methotrexate injection for rheumatoid arthritis, the compliance and the health assessment questionnaire evolution for the administration by auto-injector…
- Trial name
- Self-i (NCT02553018)
- Testing
- Methotrexate
- Where
- 2 sites in France
- Volunteers
- 278 people
- Sponsor
- Nordic Pharma SAS
Rheumatoid Arthritis
A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis Subjects
Phase 4 study to evaluate a routine patient completed assessment (RAPID3) compared to a physician completed assessment (CDAI) to predict treatment success with subjects with moderate to severe rheumatoid arthritis
- Trial name
- PREDICT (NCT01255761)
- Testing
- Certolizumab Pegol (CZP)
- Where
- 110 sites in United States
- Volunteers
- 736 people
- Sponsor
- UCB Pharma
Arthritis, Rheumatoid
Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy
This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period.
- Trial name
- NCT00603525
- Testing
- Ofatumumab
- Where
- 60 sites in Argentina, Denmark and 10 more
- Volunteers
- 169 people
- Sponsor
- GlaxoSmithKline
SLE (Systemic Lupus), RA - Rheumatoid Arthritis
Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA
The goal of this clinical trial is to inform the safety and tolerability of NTR-1011 in treating adult patients diagnosed with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- Trial name
- LIBERATE-I (NCT07237659)
- Testing
- NTR1011
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Neutrolis
Rheumatoid Arthritis
A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
This multi-center, observational study will evaluate the clinical practice patterns, efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01562327
- Testing
- Tocilizumab
- Where
- 7 sites in Argentina
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
This is a single-arm, multi-center, prospective cohort study (post-marketing observational study). The observation period for each participant is 48 weeks.
- Trial name
- NCT01346488
- Volunteers
- 2,088 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Arthritis, Rheumatoid
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this trial is to evaluate the long-term safety of BI 695500 in adult patients with moderately to severely active rheumatoid arthritis (RA) who have successfully completed treatment in Trial 1301.1.
- Trial name
- NCT01955733
- Testing
- BI 695500
- Where
- 43 sites in United States, Belgium and 7 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety
A study in Rheumatoid Arthritis (RA) patients to evaluate two formulations of adalimumab for pharmacodynamics, pharmacokinetics, and safety.
- Trial name
- NCT01712178
- Testing
- Adalimumab, current formulation, Adalimumab, new formulation
- Where
- 21 sites in United States, Belgium and 5 more
- Volunteers
- 100 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Arthritis, Rheumatoid
Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis
To investigate efficacy and safety of 3 doses of BIIL 284 BS in active rheumatoid arthritis (RA) and determine the dose with most positive efficacy / safety ratio. Pharmacokinetic profile will be also obtained.
- Trial name
- NCT02251210
- Testing
- BIIL 284 BS low dose, BIIL 284 BS medium dose, BIIL 284 BS high dose
- Volunteers
- 404 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis
CAMEO: Canadian Methotrexate and Etanercept Outcome Study
The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period
- Trial name
- NCT00654368
- Testing
- Etanercept, Methotrexate
- Where
- 28 sites in Canada
- Volunteers
- 258 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis
This is a phase 3 study to compare efficacy and safety of CT-P47 and RoActemra in patients with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT05489224
- Testing
- CT-P47, EU-approved RoActemra
- Where
- Poland
- Volunteers
- 471 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects
The primary objective in this study is to assess if single doses of BMS-986104 that are safe, tolerable, and result in sufficient lymphopenia (50% to 70% reduction in absolute lymphocyte count) can be achieved without bradycardia…
- Trial name
- NCT02211469
- Testing
- BMS-986104
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)
This will be a Phase II, multi-centre study consisting of 2 parts. Part 1: Clinical Pharmacology Study (drug-drug interaction between AK106-001616 and methotrexate) Part 2: Proof of Concept Study
- Trial name
- NCT00902369
- Testing
- AK106-001616, Active comparator
- Where
- 12 sites in Czechia, Germany and 4 more
- Volunteers
- 130 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Rheumatoid Arthritis
A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia
This is a cross-sectional, observational study examining the factors leading to the therapeutic decision to use MabThera (rituximab) in participants with RA.
- Trial name
- NCT02564770
- Where
- Australia
- Volunteers
- 167 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis RA
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
Phase 1b. To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin alfa in subjects with active rheumatoid arthritis (RA). Phase 2a.
- Trial name
- NCT03410056
- Testing
- Efavaleukin alfa
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Rheumatoid Arthritis
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)
An open-label, PhaseⅢ study to evaluate the efficacy and safety of MRA in patients with RA
- Trial name
- NCT00380601
- Testing
- MRA(Tocilizumab)
- Where
- 10 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Chugai Pharmaceutical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.